Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00120900
Status:
COMPLETED
Last Update Posted:
2017-01-19
First Post:
2005-06-30
Brief Title:
Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase III 12-week Multicentre Double-Blind Double-Dummy Randomised Placebo - and Active Comparator - Contolled Parallel Group Study to Investigate the Efficacy and Safety of GW406381 XXmg and YYmg Administered Orally Once Daily in Adults With Osteoarthritis of the Knee
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to evaluate the effectiveness of GW406381 a COX-2 inhibitor in treating the signs and symptoms of osteoarthritis of the knee
Detailed Description:
A Phase III 12-week Multicentre Double-blind Double-dummy Randomised Placebo- and Active Comparator-Controlled Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg 5mg 10mg 25mg and 50mg administered orally once daily in adults with Osteoarthritis of the knee CXA30007
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None